A co-crystal of temozolomide and hesperidin and preparation method thereof
By forming a co-crystal of temozolomide and hesperenin, the problems of poor stability and tableting performance of the two were solved, and the effect of improving stability and solubility was achieved, providing a new drug combination for cancer treatment.
Patent Information
- Application Number
- CN202010708666.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-07-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-07-22
AI Technical Summary
As two anti-tumor drugs, temozolomide and hesperenin have problems such as poor stability, poor tableting performance and low bioavailability, respectively, which limit their clinical applications.
By forming eutectics of temozolomide and hesperenin, the characteristic peaks of the X-ray powder diffraction pattern measured using Cu Kα rays are preferably orthogonal crystal system, the spatial group is Pca21, and the unit cell parameter α =β=γ=90°, eutectics are prepared in solvent by stirring or grinding.
It significantly improves the stability and tableting performance of temozolomide, improves the solubility of hesperin, provides a research basis for combined use in cancer treatment, and provides a simple preparation method suitable for industrial production.
Smart Images

Figure CN111689972B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a co-crystal of temozolomide and hesperidin and a preparation method thereof. Background Art
[0002] Drug cocrystals refer to crystals in which drug molecules and other physiologically acceptable acids, bases, salts and non-ionic compound molecules are combined in the same crystal lattice by non-covalent bonds such as hydrogen bonds, π-π stacking, and van der Waals forces. Without destroying the covalent bonds of the drug, the formation of cocrystals can change the physical and chemical properties of the drug, including stability, solubility and tableting properties. In addition, after the formation of cocrystals, some drug pharmacokinetic parameters, such as C max (peak plasma concentration), T max (peak time), t 1 / 2 (elimination half-life) and AUC (area under the plasma concentration-time curve), etc. When two drugs form a cocrystal, the purpose of combined medication can be achieved while improving the physicochemical properties and pharmacokinetic parameters of both drugs.
[0003] Temozolomide is an alkylating antitumor drug containing an imidazole tetrazine ring. Its chemical name is 3,4-dihydro-3-methyl-4-oxoimidazole [5,1-d] and 1,2,3,5-tetrazine-8-carboxamide. Its chemical structure is:
[0004]
[0005] Temozolomide is a prodrug and has no activity itself. It is converted into the active compound MITC (5-(3-methyltriazene-1-yl) imidazole-4-amide) through non-enzymatic pathways at physiological pH levels. The latter is further hydrolyzed into AIC (5-amino-imidazole-4-amide) and methyldiazonium ions. Subsequently, the methyldiazonium ions methylate DNA by acting on the O6 and N7 sites on guanine, making it unable to pair with thymine and produce cytotoxicity, exerting anti-tumor activity. The drug can pass through the blood-brain barrier, so it has a good effect on brain tumors, and also has obvious effects on leukemia, melanoma, lymphoma and solid tumors.
[0006] The drug was approved for marketing by the European Medicines Agency (EMEA) on January 20, 1999, and its approved indications are glioblastoma multiforme (brain cancer) that has progressed or recurred after conventional treatment; it was approved for marketing by the U.S. Food and Drug Administration (FDA) on August 11, 1999, and its approved indications are glioblastoma multiforme and degenerative astrocytoma. Oral capsules are commonly used in clinical practice. They are rapidly absorbed after oral administration and have high bioavailability. Pharmacokinetics show that its blood concentration reaches a peak within 1 hour, and then it is eliminated rapidly. The average half-life is 1.7 to 1.8 hours, and it is difficult to maintain an effective drug concentration at the lesion. In addition, the stability and tableting properties of temozolomide are relatively poor. In order to ensure the safety, efficacy and processability of temozolomide, it is urgently necessary to improve its stability, extend its oral half-life, and improve its tableting properties.
[0007] The chemical name of hesperetin is 4-methoxy-3,5',7'-trihydroxyflavone, and its chemical structure is:
[0008]
[0009] Hesperidin is a dihydroflavonoid compound found in citrus fruits. Its structure contains ketone carbonyl, ether bond and multiple phenolic hydroxyl groups, and has a wide range of pharmacological effects. Such as antibacterial, anti-inflammatory, antioxidant, hypoglycemic, and immune enhancement. In recent years, literature has reported that hesperidin and its derivatives also have anti-Alzheimer's disease, anti-Parkinson's disease, and anti-pulmonary, kidney, and liver fibrosis effects. In addition, hesperidin has a broad spectrum of anti-tumor activity, and has a significant inhibitory effect on a variety of tumors including brain glioma, lung cancer, ovarian cancer, liver cancer, breast cancer, etc., and can reverse tumor resistance. And hesperidin will not accumulate in any organ, and it is safe to use without obvious side effects.
[0010] Hesperidin compounds are pale yellow needle-shaped crystals that are soluble in organic solvents such as methanol, ethanol, acetone, acetonitrile, and ethyl acetate. Hesperidin is almost insoluble in water and has poor hydrophilicity, so its oral absorption is poor and its bioavailability is low, which greatly limits its clinical application. There are currently no hesperidin preparations available on the market at home and abroad.
[0011] So far, patent WO 2011 / 036676 reports the cocrystals of temozolomide and oxalic acid, succinic acid, salicylic acid, anthranilic acid, D,L-malic acid, and D,L-tartaric acid, and patent CN108623601B discloses the cocrystals of temozolomide and baicalein. In the above two patents, the stability of temozolomide in the cocrystals is significantly improved compared with the temozolomide API, and the half-life of temozolomide in the cocrystals under physiological conditions is also significantly prolonged. Other literatures report the cocrystals of temozolomide with nicotinamide, isonicotine, saccharin, caffeine, pyrazinamide, and p-hydroxybenzamide (Sanphui P, Babu NJ, Nangia A, Crystal Growth & Design, 2013, 13(5), 2208-2219). The co-crystals of hesperetin with theophylline, adenine, gallic acid and theobromine increased the solubility of the co-crystals by 2 to 4 times in the dissolution medium at pH 7.4 (Chadha K, Karan M, Chadha R, Bhalla Y, Vasisht K, Journal of Pharmaceutical Sciences, 2017, 106(8), 2026-2036). The solubility of the cocrystals of hesperetin with picolinic acid, nicotinamide, and caffeine in aqueous buffer is 4-5 times higher than that of hesperetin, and the relative bioavailability is improved (hesperetin-picolinic acid: 1.36, hesperetin-nicotinamide: 1.57, hesperetin-caffeine: 1.60) (Chadha K, Karan M, Bhalla Y, Chadha R, Khullar S, Mandal S, Vasisht K, Crystal Growth & Design, 2017, 17 (5), 2386-2405). At present, there is no report on the preparation of cocrystals of two active pharmaceutical ingredients, temozolomide and hesperetin. Through research, we have discovered a cocrystal of temozolomide and hesperetin, which can improve the stability, solubility and tableting properties of these two drugs on the one hand; on the other hand, it can be combined with temozolomide and hesperetin for the treatment of cancer, especially glioma. Summary of the invention
[0012] One of the objects of the present invention is to provide a temozolomide and hesperetin co-crystal; the second object of the present invention is to provide a method for preparing the temozolomide and hesperetin co-crystal; the third object of the present invention is to provide an application of the temozolomide and hesperetin co-crystal.
[0013] After a large number of experimental studies, the inventors tried to conduct co-crystal screening experiments on temozolomide with hesperetin, daidzein, curcumin, puerarin, etc., and finally successfully discovered the co-crystal of temozolomide and hesperetin, which can effectively improve the stability and tableting properties of temozolomide, improve the solubility of hesperetin, and slow down the dissolution of temozolomide, providing a research basis for the combined use of temozolomide and hesperetin for the treatment of cancer.
[0014] The technical solution adopted by the present invention is:
[0015] The invention provides a temozolomide and hesperidin cocrystal.
[0016] A temozolomide and hesperidin co-crystal, the structural formula of the co-crystal is shown in formula (I):
[0017]
[0018] In the cocrystal, the molar ratio of temozolomide to hesperidin is 1:1; the X-ray powder diffraction pattern of the cocrystal measured by Cu Kα rays has characteristic peaks at diffraction angles 2theta of 11.9±0.2°, 25.3±0.2°, 26.8±0.2°, and 27.1±0.2°.
[0019] Preferably, the X-ray powder diffraction pattern of the temozolomide and hesperidin cocrystal measured with Cu Kα rays also has characteristic peaks at one or more of the diffraction angles 2theta of 14.0±0.2°, 14.4±0.2°, 17.0±0.2°, 25.6±0.2°, and 26.2±0.2°.
[0020] Preferably, the temozolomide and hesperidin cocrystal is an orthorhombic system with a space group of Pca21 and a unit cell parameter of α=90°,β=90°,γ=90°;In some preferred embodiments, the unit cell parameters of the temozolomide and hesperidin cocrystal are α=90°, β=90°, γ=90°.
[0021] The invention provides a method for preparing the temozolomide and hesperidin cocrystal.
[0022] A method for preparing a temozolomide and hesperetin cocrystal comprises the following steps: adding temozolomide and hesperetin at a molar ratio of 1:1, adding a proper amount of solvent, and then obtaining the cocrystal by stirring or grinding.
[0023] Preferably, in the preparation method of the eutectic, the solvent is at least one of water, alcohol solvents, ester solvents, ketone solvents, and nitrile solvents. Among them, alcohol solvents include but are not limited to methanol, ethanol, and isopropanol; ester solvents include but are not limited to methyl acetate, ethyl acetate, and isopropyl acetate; the ketone solvents include but are not limited to acetone; nitrile solvents include but are not limited to acetonitrile; further preferably, the solvent is selected from one or more of water, methanol, ethanol, ethyl acetate, acetone, and acetonitrile.
[0024] Preferably, in the preparation method of the cocrystal, the total mass ratio of temozolomide and hesperetin to the solvent during stirring is 1 g: (4-40) mL; the total mass ratio of temozolomide and hesperetin to the solvent during grinding is 1 g: (100-200) μL.
[0025] In some preferred embodiments of the present invention, the method for preparing the co-crystal is as follows: temozolomide and hesperetin are added in a molar ratio of 1:1, a solvent is added, the mixture is stirred, filtered, and the obtained solid product is dried to obtain the co-crystal.
[0026] In some other preferred embodiments of the present invention, the method for preparing the co-crystal is specifically as follows: temozolomide and hesperetin are added in a molar ratio of 1:1, and then a solvent is added and the mixture is ground to obtain the co-crystal.
[0027] Preferably, in the method for preparing the cocrystal, the ratio of the total mass of temozolomide and hesperetin to the amount of the solvent during stirring is 1 g: (4-40) mL.
[0028] Preferably, in the method for preparing the cocrystal, the ratio of the total mass of temozolomide and hesperetin to the amount of the solvent during grinding is 1 g: (100-200) μL.
[0029] The present invention provides a pharmaceutical composition, which comprises the temozolomide and hesperidin cocrystal and a pharmaceutically acceptable excipient.
[0030] In the present invention, pharmaceutically acceptable excipients refer to pharmaceutically acceptable materials, mixtures or solvents related to the consistency of the dosage form or pharmaceutical composition. Suitable pharmaceutically acceptable excipients will vary depending on the specific dosage form selected. In addition, pharmaceutically acceptable excipients can be selected according to their specific functions in the composition.
[0031] Preferably, pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, colorants, anti-caking agents, humectants, chelating agents, plasticizers, viscosity enhancers, antioxidants, preservatives, stabilizers, surfactants and buffers.
[0032] The present invention also provides the use of the temozolomide and hesperidin cocrystal in preparing a drug for preventing and / or treating cancer.
[0033] The beneficial effects of the present invention are:
[0034] The present invention converts temozolomide into a new temozolomide and hesperetin cocrystal for the first time, which can effectively improve the stability and tableting properties of temozolomide, improve the solubility of hesperetin, slow down the dissolution of temozolomide, and provide a research basis for the combined use of temozolomide and hesperetin for the treatment of cancer.
[0035] The preparation method of the temozolomide and hesperidin cocrystal disclosed by the invention has simple process, easy control of the crystallization process, good reproducibility and is suitable for industrial production.
[0036] The temozolomide and hesperidin cocrystal of the present invention has broad application prospects in preparing drugs for preventing and / or treating cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 is the X-ray powder diffraction pattern of the temozolomide and hesperidin cocrystal prepared in Example 1;
[0038] Figure 2 is a differential scanning calorimetry analysis diagram of the temozolomide and hesperidin cocrystal prepared in Example 1;
[0039] Figure 3 is a thermogravimetric analysis diagram of the temozolomide and hesperidin co-crystal prepared in Example 1;
[0040] Figure 4 is the Fourier transform infrared spectrum of the temozolomide and hesperidin cocrystal prepared in Example 1;
[0041] Figure 5 is the hydrogen nuclear magnetic resonance spectrum of the temozolomide and hesperidin cocrystal prepared in Example 1;
[0042] Figure 6 It is a schematic diagram of the single crystal asymmetric unit of the co-crystal of temozolomide and hesperidin;
[0043] Figure 7 is a schematic diagram of the unit cell structure of temozolomide and hesperidin cocrystal;
[0044] Figure 8 It is a graph showing the content changes of temozolomide and temozolomide and hesperidin cocrystal after being placed under 40°C / 75%RH conditions for 3 months;
[0045] Fig. 9 It is the powder dissolution curve of temozolomide and temozolomide in cocrystal in pH 1.2 and pH 6.8 dissolution media;
[0046] Fig.10 It is the powder dissolution curve of hesperidin and hesperidin in cocrystal in pH 1.2 and pH 6.8 dissolution media;
[0047] Fig.11 This is a picture of temozolomide powder after being pressed under a pressure of 400MPa;
[0048] Fig.12 This is a picture of the temozolomide and hesperidin cocrystal powder after being pressed under a pressure of 400MPa;
[0049] Fig.13 It is the compressibility curve of temozolomide and temozolomide and hesperidin cocrystal powder. DETAILED DESCRIPTION
[0050] The present invention is further described in detail below by means of specific examples. Unless otherwise specified, the raw materials used in the examples can be obtained from conventional commercial sources.
[0051] Example 1
[0052] 1.94 g of temozolomide and 3.02 g of hesperidin were weighed and added to 50 mL of 80% ethanol to obtain a suspension. The suspension was stirred at room temperature for 1 h, filtered, and the obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal with a yield of 94%.
[0053] Example 2
[0054] 19.4 mg of temozolomide and 30.2 mg of hesperidin were weighed and added to 1 mL of acetone to obtain a suspension. The suspension was stirred at room temperature for 12 h and filtered. The obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal.
[0055] Example 3
[0056] 19.4 mg of temozolomide and 30.2 mg of hesperetin were weighed and added to a ball mill, and then 20 μL of ethanol was added. The mixture was ground at a frequency of 20 Hz for 30 min. The obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperetin cocrystal.
[0057] Example 4
[0058] 19.4 mg of temozolomide and 30.2 mg of hesperidin were weighed and added to a mixed solvent of 0.5 mL of ethanol and 0.5 mL of ultrapure water to obtain a suspension. The suspension was stirred at room temperature for 12 h, filtered, and the obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal.
[0059] Example 5
[0060] 19.4 mg of temozolomide and 30.2 mg of hesperidin were weighed and added to 1 mL of methanol to obtain a suspension. The suspension was stirred at room temperature for 12 h and filtered. The obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal.
[0061] Example 6
[0062] 19.4 mg of temozolomide and 30.2 mg of hesperetin were weighed, 1 mL of ethyl acetate was added to obtain a suspension, the suspension was stirred at room temperature for 12 h, filtered, and the obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperetin cocrystal.
[0063] Example 7
[0064] 19.4 mg of temozolomide and 30.2 mg of hesperidin were weighed and added to 1 mL of distilled water to obtain a suspension. The suspension was stirred at room temperature for 12 h, filtered, and the obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal.
[0065] Example 8
[0066] 19.4 mg of temozolomide and 30.2 mg of hesperidin were weighed and added to 1 mL of acetonitrile to obtain a suspension. The suspension was stirred at room temperature for 16 h and then filtered. The obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal.
[0067] Example 9
[0068] 19.4 mg of temozolomide and 30.2 mg of hesperetin were weighed, and a mixed solvent of 0.5 mL of acetonitrile and 0.5 mL of ultrapure water was added to obtain a suspension. The suspension was stirred at room temperature for 12 h, filtered, and the obtained light yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperetin cocrystal.
[0069] Example 10
[0070] 19.4 mg of temozolomide and 30.2 mg of hesperidin were weighed and added to a mixed solvent of 0.5 mL of acetone and 0.5 mL of ultrapure water to obtain a suspension. The suspension was stirred at room temperature for 12 h, filtered, and the obtained yellow solid was dried at 40° C. to obtain a solid sample of temozolomide and hesperidin cocrystal.
[0071] Characterization analysis
[0072] The present invention provides a temozolomide and hesperidin cocrystal, which is characterized by methods such as X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, Fourier transform infrared spectroscopy, and nuclear magnetic resonance hydrogen spectroscopy.
[0073] The solid sample of temozolomide and hesperidin cocrystal prepared in Example 1 was subjected to X-ray powder diffraction analysis using a Bruker D2 PHASER diffractometer from Bruker Instruments Ltd., Germany, Cu Kα radiation, a voltage of 30 kV, a current of 10 mA, a step length of 0.01°, a scanning speed of 10° / min, a scanning range of 5.0 to 40.0°, and a test temperature of room temperature. The analysis results are shown in the attached Figure 1 The X-ray powder diffraction pattern of , and the X-ray powder diffraction data are shown in Table 1.
[0074] Table 1 X-ray powder diffraction data of temozolomide and hesperidin cocrystal of Example 1
[0075]
[0076] Based on the same X-ray powder diffraction test method as in Example 1, the X-ray powder diffraction data of the solid sample of temozolomide and hesperidin co-crystal prepared in Example 2 are shown in Table 2.
[0077] Table 2 X-ray powder diffraction data of temozolomide and hesperidin cocrystal of Example 2
[0078]
[0079]
[0080] Based on the same X-ray powder diffraction test method as in Example 1, the X-ray powder diffraction data of the solid sample of temozolomide and hesperidin co-crystal prepared in Example 3 are shown in Table 3.
[0081] Table 3 X-ray powder diffraction data of temozolomide and hesperidin cocrystal of Example 3
[0082]
[0083] It is well known to those skilled in the art that crystalline materials can be characterized by X-ray diffraction technology, but X-ray diffraction patterns usually change with the test conditions of the instrument. It is particularly important to point out that the relative intensity of the X-ray diffraction pattern may change with the change of experimental conditions, so the relative intensity order of the X-ray diffraction peaks cannot be used as the only or decisive factor in the characterization of crystalline materials. In addition, the peak angle is usually allowed to have an error of ± 0.2 °. Due to the influence of experimental factors such as sample height and test temperature, the overall deviation of the peak angle will be caused, and a certain deviation is usually allowed. Therefore, it is understood by those skilled in the art that the X-ray diffraction pattern of the temozolomide and hesperidin cocrystal of the present invention does not have to be completely consistent with the X-ray diffraction pattern in this embodiment, and any situation with the same or similar characteristic peaks as in this spectrum belongs to the scope of the present invention. Those skilled in the art can compare the spectrum listed in the present invention with the spectrum of an unknown substance to confirm whether the unknown substance is or is not the temozolomide and hesperidin cocrystal of the present invention.
[0084] The solid sample of temozolomide and hesperidin cocrystal prepared in Example 1 was subjected to differential scanning calorimetry analysis using a DSC 214 differential calorimeter manufactured by NETZSCH Scientific Instruments Co., Ltd., Germany, with a nitrogen atmosphere and a heating rate of 10°C / min. The analysis results are shown in the attached Figure 2 Differential scanning calorimetry analysis diagram of Figure 2 As shown, no obvious endothermic or exothermic phenomenon was found in the co-crystal of temozolomide and hesperetin before thermal decomposition.
[0085] The solid sample of temozolomide and hesperidin cocrystal prepared in Example 1 was subjected to thermogravimetric analysis using a TG209 F3 thermogravimetric analyzer from German NETZSCH Scientific Instruments Co., Ltd., with a nitrogen atmosphere and a heating rate of 10°C / min. The analysis results are shown in the attached Figure 3 Thermogravimetric analysis diagram of Figure 3 As shown, the temozolomide and hesperetin cocrystal begins to decompose when heated to around 200°C, and there is no weight loss before this temperature.
[0086] The temozolomide and hesperidin cocrystal sample prepared in Example 1 was subjected to infrared spectroscopy analysis using a Bruker Vertex 70 Fourier transform infrared spectrometer with a detection range of 4000 to 500 cm -1 The analysis results are attached. Figure 4 Fourier transform infrared spectrum of Figure 4 It can be seen that the characteristic peak position of its infrared spectrum is (cm -1): 3464, 3301, 3130, 1743, 1699, 1635, 1591, 1512, 1485, 1460, 1357, 1299, 1269, 1201, 1163, 1078, 1047, 1020, 947, 883, 840, 796, 765, 734, 703, 611, 563, 513.
[0087] The temozolomide and hesperidin co-crystal sample prepared in Example 1 was subjected to nuclear magnetic resonance hydrogen spectrum analysis using an Avance III 400 M nuclear magnetic resonance spectrometer from Bruker, Germany. The analysis results are shown in the attached Figure 5 The H NMR spectrum of Figure 5 It can be seen that the peak of temozolomide is: 1 H NMR (400 MHz, DMSO) δ 8.83 (s, 1H), 7.81 (s, 1H), 7.69 (s, 1H), 3.87 (s, 3H); the peaks of hesperidin are: 1 H NMR (400MHz, DMSO) δ12.14 (s, 1H), 10.80 (s, 1H), 9.11 (s, 1H), 6.91 (dd, J = 25.3, 8.4 Hz, 3H), 5.89 (dd, J = 5.6, 2.1 Hz, 2H), 5.44 (dd, J = 12.3, 3.0 Hz, 1H), 3.78 (s, 3H), 3.21 (dd, J = 17.1, 12.4 Hz, 1H), 2.71 (dd, J = 17.1, 3.1 Hz, 1H). According to the integration results of each peak, the stoichiometric ratio of temozolomide to hesperidin in the cocrystal is 1:1.
[0088] Single Crystal Study of Temozolomide and Hesperidin Cocrystal
[0089] Take 4 mL of mixed solvent (acetonitrile: water = 3: 1), add the co-crystal sample of muzolomide and hesperidin prepared in Example 1 until supersaturated, filter, and place the filtrate at room temperature to slowly evaporate for 2 days to obtain light yellow transparent flaky crystals.
[0090] X-ray single crystal diffractometer model: XtaLAB min system;
[0091] wavelength:
[0092] Test temperature: 293K;
[0093] Computer programs used for structure elucidation: Olex2;
[0094] Experimental formula: C 22 H 17 N6O8;
[0095] Molecular weight: 493.41;
[0096] Crystal system: orthorhombic;
[0097] Space group: Pca21;
[0098] Unit cell parameters:
[0099]
[0100]
[0101]
[0102] α=90°;
[0103] β=90°;
[0104] γ=90°;
[0105] Unit cell volume:
[0106] Z (the number of experimental formulas contained in the unit cell): 4;
[0107] Calculated density: 1.471 g / cm 3 .
[0108] Structural description: Single crystal diffraction and structural analysis show that the asymmetric structural unit of the crystal contains one temozolomide molecule and one hesperidin molecule. The unit cell of the crystal contains four temozolomide molecules and four hesperidin molecules. The schematic diagram of the asymmetric structural unit is shown in the attached figure. Figure 6 The schematic diagram of the unit cell is shown in the attached Figure 7 shown.
[0109] Stability studies
[0110] The stability of temozolomide and temozolomide-hesperetin cocrystal was compared.
[0111] Source of the tested samples: Temozolomide and hesperidin cocrystal was prepared by the method provided in Example 1 of the present invention; Temozolomide API was purchased from Shanghai Shengde Pharmaceutical Technology Co., Ltd. with a purity of 98%.
[0112] Accelerated stability test: Take a certain amount of temozolomide and temozolomide and hesperidin cocrystal powder samples in a 10 mL small beaker, and place it open at a constant temperature and humidity of 40°C / 75%RH. Samples were taken at the end of 0, 1, 2, and 3 months to detect the content of temozolomide by high performance liquid chromatography.
[0113] The experimental results are attached. Figure 8The drug content of temozolomide raw material showed a sharp decline over time, and the drug content at the end of 1 month, 2 months and 3 months dropped to 97.46% ± 2.45%, 65.43 ± 0.76% and 31.64 ± 0.64%, respectively; in contrast, the content of temozolomide in the cocrystal did not decrease, and was still 103.30 ± 4.70% at the end of 3 months. This shows that the stability of temozolomide and hesperidin cocrystal is better than that of temozolomide.
[0114] Solubility evaluation
[0115] The powder dissolution data of temozolomide, hesperetin, and temozolomide and hesperetin cocrystal were compared.
[0116] Source of the tested samples: Temozolomide and hesperetin cocrystals were prepared by the method provided in Example 1 of the present invention; temozolomide and hesperetin APIs were purchased from Shanghai Shengde Pharmaceutical Technology Co., Ltd., with a purity of 98%.
[0117] Powder dissolution test method: After grinding the powder samples of temozolomide, hesperetin, and temozolomide and hesperetin cocrystal, the powder samples were sieved with 100 and 200 meshes respectively to control the particle size between 75 and 150 μm. For the hydrochloric acid solution with pH 1.2, 500 mg of temozolomide, 778 mg of hesperetin, and 1278 mg of temozolomide and hesperetin cocrystal were weighed respectively; for the phosphate buffer solution with pH 6.8, 600 mg of temozolomide, 934 mg of hesperetin, and 1534 mg of temozolomide and hesperetin cocrystal were weighed respectively, added to the dissolution medium and stirred, 0.2 mL of the solution was taken at intervals, filtered through a 0.45 μm microporous filter membrane, and diluted to an appropriate multiple, and the drug concentration at each time point was monitored by high performance liquid chromatography to finally obtain the powder dissolution curve of each sample.
[0118] Powder dissolution conditions:
[0119] Dissolution medium: pH 1.2 hydrochloric acid solution and pH 6.8 phosphate buffer solution
[0120] Dissolution medium volume: 45mL
[0121] Stirring speed: 150 rpm
[0122] Dissolution temperature: 37±0.5℃;
[0123] Sampling time: 0.16, 0.5, 1, 2, 3, 5, 10, 20, 30, 60, 120, 240 minutes;
[0124] Liquid phase conditions:
[0125] Instrument: SHIMADZU LC-2030C 3D;
[0126] Chromatographic column: Inertsil ODS C18 column (4.6 mm × 150 mm, 5 μm);
[0127] UV detection wavelength: temozolomide 329nm, hesperetin 288nm;
[0128] Mobile phase: methanol / pH 2.8 acetic acid aqueous solution gradient elution (0-7min: 10% methanol; 8-16min: 60% methanol; 17.5-20min: 10% methanol)
[0129] Column temperature: 35 °C;
[0130] Flow rate: 1 mL / min;
[0131] Injection volume: 20 μL.
[0132] The experimental results are attached. Fig. 9 and Fig.10 The temozolomide in the cocrystal provided by the present invention has a slower dissolution rate than the temozolomide API, while the hesperidin in the cocrystal has a faster dissolution rate than the hesperidin API. Fig. 9 As shown in the figure, in the dissolution medium of pH 1.2, the maximum dissolution concentration of temozolomide in the cocrystal within 4 hours was 0.48±0.01 mg / mL, which was reduced to 1 / 15 of the temozolomide API; in the dissolution medium of pH 6.8, the maximum dissolution concentration of temozolomide in the cocrystal within 4 hours was 0.19±0.02 mg / mL, which was reduced to 1 / 30 of the temozolomide API. This may be because temozolomide is gradually hydrolyzed into AIC under a higher pH environment, resulting in a lower drug concentration. As shown in the attached figure Fig.10 As shown in the figure, in the dissolution medium of pH 1.2, the hesperidin in the cocrystal dissolved rapidly within 1 minute, and the maximum dissolution concentration reached 31.68±2.44μg / mL, which was 17.5 times that of the hesperidin API; in the dissolution medium of pH 6.8, the hesperidin in the cocrystal dissolved rapidly within 10 minutes, and the maximum dissolution concentration reached 20.67±3.13μg / mL, which was 25.8 times that of the hesperidin API.
[0133] Tableting performance evaluation
[0134] Comparative study on tableting properties of powder samples of temozolomide and temozolomide-hesperetin cocrystal
[0135] Source of the tested samples: Temozolomide and hesperidin cocrystal was prepared by the method provided in Example 1 of the present invention; the temozolomide raw material was purchased from Shanghai Shengde Pharmaceutical Technology Co., Ltd. with a purity of 98%.
[0136] After grinding the powder samples of temozolomide and temozolomide and hesperidin cocrystal, they were sieved with 100 and 200 meshes respectively, and the particle size was controlled at 75-150 μm. After standing for 1 week, the Specac GS01190 tablet press and tablet pressing mold were used to adjust the pressure from 100 to 400 MPa to press and press into tablets with a diameter of 5 mm. Temozolomide powder cannot be pressed into tablets within the range of 100 to 400 MPa, indicating that the tableting performance is very poor. In contrast, temozolomide and hesperidin cocrystal powder can be pressed into complete tablets within the range of 100 to 400 MPa, indicating that its tableting performance is significantly improved. The pictures of the powders of temozolomide and temozolomide and hesperidin cocrystal pressed under a pressure of 400 MPa are attached. Fig.11 and Fig.12 .like Fig.11 As shown in Figure 2, temozolomide powder cannot be compressed into tablets. Fig.12 As shown, the temozolomide and hesperidin co-crystal powder can be compressed into tablets.
[0137] After the tablets of temozolomide and hesperidin cocrystal were placed for 24 hours, all the tablets remained intact without any signs of cracking or delamination. The diameter, thickness and weight of the tablets were measured, and the hardness of the tablets was measured using the Tianda Tianfa YD-20KZ intelligent tablet hardness tester. The experimental results are attached. Fig.13 Tabletability curve. Fig.13 As shown in the figure, the temozolomide powder cannot be pressed into tablets, so the hardness is 0; in contrast, the hardness of the temozolomide and hesperidin cocrystal tablets is much higher than that of temozolomide. It can be seen that the formation of cocrystals significantly improves the tableting performance of temozolomide.
[0138] The temozolomide and hesperidin cocrystal provided by the present invention can be used to prepare drugs for preventing and / or treating cancer, and has broad application prospects.
[0139] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A temozolomide and hesperidin cocrystal, Features: The structural formula of the co-crystal is shown in formula (I): In the co-crystal, the molar ratio of temozolomide to hesperidin is 1:1; the X-ray powder diffraction pattern of the co-crystal measured by Cu Kα rays has characteristic peaks at 2theta values of 11.9±0.2°, 14.4±0.2°, 25.3±0.2°, 25.6±0.2°, 26.8±0.2°, and 27.1±0.2°.
2. The co-crystal according to claim 1, wherein the X-ray powder diffraction pattern of the co-crystal further has characteristic peaks at one or more of the 2theta values of 14.0±0.2°, 17.0±0.2°, and 26.2±0.2°.
3. The eutectic according to any one of claims 1 to 2, Features: The eutectic is an orthorhombic system with a space group of Pca2 1 , the unit cell parameters are α=90°, β=90°, γ=90°.
4. A method for preparing the co-crystal according to any one of claims 1 to 3, Features: The method comprises the following steps: adding temozolomide and hesperetin in a molar ratio of 1:1, adding a proper amount of solvent, and then obtaining a cocrystal by stirring or grinding.
5. The preparation method according to claim 4, Features: The solvent is at least one of water, alcohols, esters, ketones and alkyl nitriles.
6. The preparation method according to claim 4, Features: During the stirring, the total mass of temozolomide and hesperetin to the solvent is in the ratio of 1 g: (4-40) mL.
7. The preparation method according to claim 4, Features: During the grinding, the total mass of temozolomide and hesperetin to the solvent is in the ratio of 1 g: (100-200) μL.
8. A pharmaceutical composition, Features: The invention comprises the co-crystal according to any one of claims 1 to 3 and a pharmaceutically acceptable excipient.
